anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: I. Estimate the maximum tolerated dose (MTD) of ecteinascidin-743 (ET-743) when administered as a single intravenous infusion every 21 days in adults with solid tumors not amenable to standard therapy. II. Describe the qualitative and quantitative toxic effects of ET-743, and study the predictability, duration, intensity, onset, reversibility, and dose-relationship of these toxic effects in these patients. III. Propose a safe dose for a phase II study based on the MTD determined on this study. IV. Assess the pharmacokinetics of ET-743 at different dose levels. V. Document any antitumor effects of ET-743 in these patients.

OUTLINE: This is a multicenter study. All patients receive ET-743 IV over 3 hours every 21 days for 4 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of ET-743 until the maximum tolerated dose is determined. Patients are followed at 1 month, then every 3 months until disease progression.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study over 12 months.
Fish oil supplements will be given to subjects with different variants in the promoter region of the arachidonate 5-lipoxygenase (ALOX5) gene and outcome measures will be evaluated after 6 wk of supplementation. These outcomes include ALOX5 protein levels (also called 5-lipoxygenase, or 5-LO), leukotriene levels, markers of inflammation, and blood lipids. The 5-LO enzyme converts arachidonic acid (AA) to leukotrienes that promote inflammation. Subjects with different promoter variants are hypothesized to have different basal or stimulated levels of 5-LO expression. Preliminary data suggests that subjects with a promoter variant that causes increased 5-LO expression also may have a "better" anti-inflammatory or lipid-lowering response to fish oil supplements. The homozygous variant genotype is much more common in African Americans than other groups thus we propose to conduct the study in African Americans. The fish oil eicosapentaenoic acid (EPA) competitively inhibits conversion of AA to pro-inflammatory 4-series leukotrienes.

The grant proposes to conduct a community-based, double-masked, randomized, placebo-controlled trial; n = 15/group, total = 166 (genotypes 44 will have n = 8). The intervention group will receive 5.0 g/d fish oil concentrate (3.0 g/d EPA + DHA) for 6 wk. The study will be conducted in Oakland, Davis, and Sacramento, California where African Americans 20 - 59 y of age without serious chronic disease will be recruited.

A recent observational study indicates that subjects with a variant allele for ALOX5 may be at greater risk for cardiovascular disease and, at the same time, may derive a greater benefit from omega-3 fatty acid supplements than do subjects homozygous for the common allele. The variant alleles are less common in the white population (18%) than in the black population (52%). Since African Americans have a higher prevalence of cardiovascular disease and of the ALOX5 variant alleles, as shown in epidemiologic studies, they may have a greater benefit from omega-3 supplementation in the reduction of inflammation and cardiovascular risk factors. Recruitment will be conducted through the community service, Ethnic Health Institute (EHI), of Alta Bates Summit Medical Center in conjunction with UCD, and outreach efforts from the USDA, ARS, Western Human Nutrition Research Center (WHNRC) at UC Davis. We will determine if subjects with one or two variant ALOX5 alleles have higher ALOX5 gene expression, higher production of AA-derived leukotrienes, and a better response to omega-3 supplements than do subjects homozygous for the common allele.
The Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub Arm receives all 3 interventions. Participants receive weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective, Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention and has social needs addressed through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
PROBLEM TO BE SOLVED: To produce a denture in a relatively short time with dimensional stability free from defects pertaining to strength, discoloring, attack by plaque and grinding performance. SOLUTION: In the production method of the denture, a precision impression mold is produced using impression agents and a working model is made. A denture base comprising a hardenable material is applied to further harden the work and an insulating layer is applied on the denture base and teeth are arranged on the insulated denture base in the form of wax. A dental arch is fixed using an imbedding agent and the wax work is boiled up to remove so that a hollow portion generated after the removal of the wax by boiling is filled with the denture material. A precision impression mold is produced by further hardening the work or using impression agents and a working model is made. A denture base comprising a photosetting denture material is applied to further harden the work and the arraying of teeth is implemented in the photosetting denture material. Then, the work is further hardened.
The invention discloses a medicine for preventing and treating infectious bursal disease of chicken. The traditional Chinese medicine is prepared from the following traditional Chinese medicines in a certain proportion: radix isatidis, folium isatidis, dandelion, common andrographis herb, honeysuckle, scutellaria baicalensis, fructus forsythiae, golden cypress, gypsum, rhizoma anemarrhenae, radix rehmanniae, astragalus mongholicus, radix scrophulariae, hairyvein agrimony, rheum officinale, fructus gardeniae and liquorice. Pulverizing the above materials, grinding, mixing, and stirring. In clinical application, the medicine is soaked in boiling water for 30-60 min to dissolve out the effective components of the medicine, and this is favorable to the absorption of sick chicken in body. The medicine has high clinical cure rate, no adverse reaction, no medicine residue and no hidden danger of drug resistance. Easily-accessible raw materials, simple preparation method, definite therapeutic effect, convenient use, and wide application in chicken raising industry.
Alprazolam is a triazolo analog of the 1,4 benzodiazepine class of central nervous system-active compounds. The chemical name of alprazolam is 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo [4,3-α] [1,4] benzodiazepine. The structural formula is:

  


Alprazolam is a white to off-white crystalline powder, which is soluble in alcohol but which has no appreciable solubility in water at physiological pH.

Each alprazolam tablet, for oral administration, contains 0.25, 0.5, or 1 mg of alprazolam. Inactive ingredients: docusate sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch, and sodium benzoate.

Alprazolam is a white to off-white crystalline powder, which is soluble in alcohol but which has no appreciable solubility in water at physiological pH. Additionally, the 0.5 mg also contains FD and C Yellow No. 6 Aluminum Lake, and the 1 mg also contains FD and C Blue No. 2 Aluminum Lake.
The invention provides a formononetin derivative, a preparation method thereof, a pharmaceutical composition and application thereof, and belongs to the technical field of medicines. The formononetin derivative provided by the invention has good anti-tumor effect, the anti-tumor effect of most derivatives is superior to that of a positive control drug 5 fluorouracil, especially the compound 3, has good proliferation inhibition effect on human gastric cancer cells HGC-27 and human non-small cell lung cancer cells A945, and has good proliferation inhibition effect on IC  50  The values were 4.77.+ -. 0.29. Mu.M and 4.95.+ -. 1.38. Mu.M, respectively. Meanwhile, in 18 derivatives, the proliferation inhibition effect of 7 compounds on human breast cancer cells MCF-7 is improved compared with formononetin, and the proliferation inhibition effect of 7 compounds is better than that of yangSex control 5-fluorouracil, wherein Compound 1 has the strongest proliferation inhibition effect on human breast cancer cell MCF-7, IC  50  ＝24.25±2.09μM。
Enrollment will begin after the safety data from groups 1A and 2A has been examined. Participants in this group will receive a total of two scarification immunizations by 5 needles used to administer 15 jabs, each containing, 20 mg/ml of KLH carrier-protein. Immunizations will occur 21 days apart at Visits 5 and 6.
Proliferating pancreatic islet cells obtained by the method of isolating a population of cells that preferably includes predominantly islet precursor cells that express one or more marker associated with an islet precursor cell and providing the precursor cells with one or more a pancreatic differentiation agent so that a population of cells is obtained that has a high proportion of cells with phenotypic characteristics of functional pancreatic islet .beta.-cells. Optionally, the precursor cells are pretreated by providing them with one or more cell expansion agent to increase the number of cells in the population prior to differentiation. The pancreatic differentiation agent composition comprises a gastrin/CCK receptor ligand, e.g., a gastrin, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The cell expansion agent composition comprises one or more epidermal growth factor (EGF) receptor ligand in an amount sufficient to stimulate proliferation of the precursor cells. The methods of treatment include transplanting either undifferentiated precursor cells and providing the pancreatic differentiation agent either alone or in combination with the cell expansion agent in situ, or transplanting the functional pancreatic islet .beta.-cells into the patient.  The pancreatic islet .beta.-cells can be used for drug screening, and replenishing pancreatic function in the context of clinical treatment.
In the context of the alarming rise of infant obesity and its health implications, the present research aims to uncover disruptions in postprandial lipid metabolism and the composition of triglyceride-rich lipoproteins in obese adolescents. A double-blind, controlled clinical trial in the postprandial phase on 23 adolescents aged 12 to 16 years was carried out. Twelve participants were categorized as obese (BMI > 30 kg/m2 and percentile > 95) and 11 as normal-weight (BMI = 20-25 kg/m2, percentile 5-85). Blood samples were collected after a 12-h overnight fast and postprandially after consumption of a standardized breakfast containing olive oil, tomato, bread, orange juice, and skimmed milk. Obese adolescents exhibited elevated triglyceride concentrations in both fasting and postprandial states and higher TG/apo-B48 ratios, indicating larger postprandial triglyceride-rich lipoprotein (TRL) particle size, which suggests impaired clearance. Obese subjects also exhibited higher n-6 PUFA concentrations, potentially linked to increased TRL hydrolysis and the release of pro-inflammatory adipokines. In contrast, TRL from normal-weight individuals showed higher concentrations of oleic acid and DHA (n-3 PUFA), with possible anti-inflammatory effects. The results indicate an interplay involving postprandial TRL metabolism and adipokines within the context of adolescent obesity, pointing to potential cardiovascular implications in the future.
A peroral pharmaceutical formulation for controlled release of a drug contains a mixture of the drug and a polymer for controlling its release. The polymer is chitosan, particularly microcrystalline chitosan with a high crystallinity degree, and the mixture of the chitosan and the drug is in the form of granules or pellets. The preparation can be a dosage bag, a gelatine capsule or a compressed tablet containing the granules or pellets. The preparation can be best utilized in the administration of drugs which are only absorbed at the initial end of the gastrointestinal tract (e.g. furosemide) or which form undesirable metabolites when passed to the terminal end of the gastrointestinal tract, or which are susceptible of irritating the mucous membrane of the stomach (e.g. anti-inflammatory analgesics and corticoids).
Subjects will receive standard of care hip decompression along with an injection of approximately 5 mls. of lactated ringers.
The invention discloses a Chinese patent drug and a traditional Chinese medicine decoction capable of treating lung abscess effectively and belongs to the field of biology and medicine. The traditional Chinese medicine decoction is characterized by being prepared by seven types of traditional Chinese medicines of a traditional Chinese medicine formula, and the traditional Chinese medicine formula is a proved recipe of a chief physician of a certain hospital. The traditional Chinese medicine decoction is proved to have good cure effect to lung abscess. Pills, powders, granules, tablets, capsules and the like of the Chinese patent drug can be developed according to the traditional Chinese medicine formula which is the proved recipe. Advantages of the Chinese patent drug can be functioned, and the Chinese patent drug is available, meets requirements in emergency, can be stored conveniently and is portable. Accordingly, development of the traditional Chinese medicine decoction and the Chinese patent drug has a good commercial development prospect.
Participants receive BL-M14D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
Patients receive a physical examination during visit 1. A stool sample, blood sample, and 6 biopsies are collected at visit 2, and patients undergo a flexible fiberoptic sigmoidoscopy. Patients receive idelalisib PO twice daily BID after visit 2. Treatment continues in the absence of disease progression or unacceptable toxicity. A third research visit occurs upon development of idelalisib-associated diarrhea/colitis symptoms. Patients with diarrhea/colitis symptoms undergo a full colonoscopy and collection of stool and blood samples. Control patients with no diarrhea/colitis symptoms undergo all needed tests and assessments including a flexible fiberoptic sigmoidoscopy and collection of stool and blood samples. All patients undergo optional biospecimen collection at the time of disease progression.
The small randomized controlled trial of an intensive curriculum and school garden intervention was implemented in elementary schools in two communities (Shiprock and Tsaile). The study began in year 1 with a period of engagement and recruitment of schools in each community; with the goal of recruiting three schools in each community to complete the run-in phase. The run-in period included time for greater engagement with the school community, an assessment of the potential garden site and an assessment of evaluation readiness. Depending on whether three schools in the community qualify for the study at the end of run-in, or only two schools per community, it was planned to randomize three or two schools to intervention or delayed intervention status in each community. Six schools were randomized, two intervention schools and 4 comparison (delayed intervention) schools. Baseline data collection was conducted at the beginning of the school year 2019-2020 in Year 2 with 3rd and 4th grade children. Students in the intervention schools received the curriculum and school garden during that academic school year (Study Year 2). At the end of the school year, 8-month follow-up assessment was conducted. The main evaluation period is between baseline and 8-month follow-up, and the statistical analysis methods estimate the differential change in outcome measures (healthy eating and gardening).

Not part of the clinical trial, the study continued in the next school year (2020-2021). At the beginning of Study Year 3, the comparison schools were scheduled to receive the delayed intervention. During Study Year 3, it was planned to conduct quarterly community gardening workshops for adult family members in all schools. Due to the COVID-19 pandemic, a series of 10 video workshops were produced and made available via YouTube. Attendance/Views were tracked. A final assessment survey was conducted at the end of that school year (in 2021) in all 6 schools to allow additional descriptive analyses.
INTRODUCTION: The community deintensification rates in older people with diabetes are low and hospital admission presents an opportunity for medication review. We audited the inpatient assessment and deintensification rate in people with diabetes and frailty. We also identified factors associated with adverse inpatient outcomes.
METHODS: A retrospective review of electronic charts was conducted in all people with diabetes and clinical frailty score ≥6 who were discharged from the medical unit in 2022. Data on demographics, comorbidities and background glucose-lowering medications were collected.
RESULTS: Six-hundred-and-sixty-five people with diabetes and moderate/severe frailty were included in our analysis. For people with no HbA1c in the last six months preceding admission, only 9.0% had it assessed during inpatient. Deintensification rates were 19.1%. Factors that were associated with adverse inpatient outcomes included inpatient hypoglycaemia, non-White ethnicity, and being overtreated (HbA1c <7.0% [53 mmol/mol] with any glucose-lowering medication).
CONCLUSION: The assessment and deintensification rate in secondary care for people with diabetes and frailty is low. Inpatient hypoglycaemia, non-White ethnicity, and overtreatment are important factors in determining inpatient outcomes highlighting the importance of deintensification and the need for an evidence-based risk stratification tool.
Patients with CD38 positive multiple myeloma with be enrolled. Patients will undergo pretreatment evaluation with standard of care diagnostic tests, as well as experimental 89Zr-daratumumab PET/CT. Patients will then undergo a course of standard of care therapy as defined by a medical oncologist. Following therapy, patients will repeat standard of care diagnostic tests, as well as experimental 89Zr-daratumumab PET/CT. Data analysis will be performed to evaluate 89Zr-daratumumab against standard of care diagnostic tests for the detection and localization of active disease before and after therapy.
PURPOSE:To obtain the ester useful for the therapy and prophylaxis of diseases caused by HIV by reacting an N-acetylneuraminic acid homopolymer with a specified amount of a catalyst and a specified amount of a sulfating agent. CONSTITUTION:1pt.wt. N-acetylneuraminic acid homopolymer is reacted with 0.5-200 pts.wt. catalyst (e.g. pyridine) and 0.2-30 pts.wt. sulfating agent (e.g. chlorosulfonic acid) in the presence or absence of a solvent to obtain the ester represented by the formula (wherein R is H or SO3H; and n is 5-1000, provided that the number of the SO3H residues is 0.1-3 per residue of N-acetylneuraminic acid). This ester has an antihuman immuno-deficiency virusactivity nearly equivalent to that of conventional sulfated polysaccharides, has no side effects such as a heretofore problematic anticoagulant activity and is lowly cytotoxic, so that it is useful for the therapy and prophylaxis of diseases caused by human immuno-deficiency viruses.
IV daratumumab 16mg/kg body weight weekly for weeks 1-9 followed by daratumumab 16mg/kg body weight once every 3 weeks from weeks 10 to 24 and then daratumumab 16mg/kg once every 4 weeks from weeks 25 onwards until disease progression; S.C bortezomib and PO Dexamethasone 40mg (starting dose of dexamethasone is 20mg once weekly for patients \>75 years old) once weekly for 9 months from start of study. After 9 months, patient only continues on daratumumab until progression.
The present invention refers to an essential oil product obtained from chia seeds, which mainly refers to the genus and species of Salvia hispanica pertaining to any of the following families: Labiate or Lamiaceae or Linnaeus, which also includes the varieties commercially known as: White chia seeds, mixture of different colour chia seeds, black chia seeds golden chia seeds, Anutra and Salba; the invention also refers to the process for extracting oil therefrom. According to one embodiment, chia seeds may be toasted in order to optimise the yield thereof. Seeds are pressed for extracting the oil therefrom. The remaining seed paste (dough) is separated so that it may be used in further processes. The extracted oil is filtrated for separating the seed rests and subsequently deodorised using active carbon. The resulting oil is bottled for the preservation thereof and then used in different industries such as food, cosmetic, artistic, potting and fur trade industries.
A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having a relatively rapid dissolution rate in aqueous media. Also provided are novel solvated crystalline forms of eplerenone that, when desolvated, can yield Form H eplerenone. Also provided is amorphous eplerenone. Pharmaceutical compositions are provided comprising Form H  eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form H eplerenone and for preparing compositions comprising Form H eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form H eplerenone.
PURPOSE: A sustained release tablet containing trimebutin is provided to ensure excellent pharmacological effect and to improve drug compliance. CONSTITUTION: A sustained release tablet containing trimebutin comprises: an upper layer, a lower layer, and a film coated layer. The upper layer comprises 100-110 weight parts of trimebutine maleate, 12-30 weight parts of polyethylene oxide, and 6-20 weight parts of hypromellose. The lower layer contains 190-200 weight parts of trimebutin meleate, 25-55 weight parts of polyethylene oxide, and 10-35 weight parts of hypromellose. The upper and lower layers contain a coloring agent. The film coated layer covers the upper and lower layers.
Lorazepam bolus is to be injected based on information from the patient leaflet/package insert. The rate of injection should not exceed 2.0 mg/min. The LZP dose will be determined according to the Investigator's clinical judgment.